EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)

Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Emmanuel Seront, Javier Molina-Cerrillo, Renate Pichler, Zin W Myint, Jakub Kucharz, Ravindran Kanesvaran, Thomas Büttner und 24 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-04043-x ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Matteo Santoni und 35 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Unit, Macerata Hospital, Macerata, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Antibodies, Monoclonal, Humanized, Nivolumab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal first-line therapy for metastatic renal cell carcinoma (mRCC) remains uncertain, despite recent advancements in immune-based combinations. This retrospective study compares the effectiveness of pembrolizumab plus axitinib (PA) and nivolumab plus cabozantinib (NC) as first-line treatments for mRCC in a real-world setting.

Methods

Patient data were collected from 55 centers across 16 countries, encompassing individuals diagnosed with mRCC receiving first-line treatment with PA or NC between January 2016 and October 2023. Clinical and tumor features and treatment responses were recorded. The primary endpoints were overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and time to second progression. Statistical analyses included Kaplan–Meier survival estimates, Cox proportional hazard models, and chi-square tests.

Results

A total of 760 patients with a median age of 64 years (range, 29–88) were included. Of them, 607 received PA, and only 153 NC. In the overall study population, ORR was 59% for and 49% for PA. Median OS was 55.7 months and not reached (NR) for PA and NC, respectively ( P = .51), while median PFS was longer with NC (27.6 months) than for PA (16.2 months, P = .003). Subgroup analysis suggested a PFS benefits for NC in male, younger patients, intermediate risk group, clear cell histology, and lung involvement, as well as ORR favored NC in good risk patients. Multivariate analysis identified first-line therapy as a significant factor associated with PFS.

Conclusions

In this certainly biased retrospective comparison, NC demonstrated superior ORR and longer PFS compared to PA in mRCC. These findings underscore the importance of considering individual patient characteristics and risk profiles when selecting first-line therapy for mRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsAntibodies, Monoclonal, HumanizedNivolumabAntineoplastic Combined Chemotherapy ProtocolsAxitinibAnilidesHumansMaleRetrospective StudiesMiddle AgedFemaleAgedAdultAged, 80 and overPyridines

Stichwörter der Autor:innen

ARON-1 studyAxitinib plus pembrolizumabCabozantinib plus nivolumabImmune-oncology combinations

Substanzen

Antibodies, Monoclonal, HumanizedNivolumabpembrolizumabcabozantinibAxitinibAnilidesPyridines

Autor:innen und Institutionen

  • Oncology Unit, Macerata Hospital, Macerata, Italy.
  • Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Viale Pieraccini 6, 50139, Florence, Italy. giandomenico.roviello@unifi.it.
  • Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
  • Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Medical Oncology, Cliniques Universitaires Saint-Luc 1200, Brussels, Belgium.

Förderung

  • NCI NIH HHS

Zitieren

APA

Santoni, M., Roviello, G., Grande, E., De Giorgi, U., Fiala, O., Seront, E., Molina-Cerrillo, J., Pichler, R., Myint, Z. W., Kucharz, J., Kanesvaran, R., Büttner, T., Pichler, M., Basso, U., Kopecky, J., Bourlon, M. T., Cerbone, L., Buchler, T., Pinto, A., …, & Massari, F. (2025). Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04043-x

Vancouver

Santoni M, Roviello G, Grande E, De Giorgi U, Fiala O, Seront E, et al. Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1). Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04043-x

BibTeX
@article{Santoni2025,
  author = {Santoni, Matteo and Roviello, Giandomenico and Grande, Enrique and De Giorgi, Ugo and Fiala, Ondrej and Seront, Emmanuel and Molina-Cerrillo, Javier and Pichler, Renate and Myint, Zin W and Kucharz, Jakub and Kanesvaran, Ravindran and Büttner, Thomas and Pichler, Martin and Basso, Umberto and Kopecky, Jindrich and Bourlon, Maria T and Cerbone, Linda and Buchler, Tomas and Pinto, Alvaro and de Liaño, Alfonso Gómez and Gianni, Caterina and Zgura, Anca and Rescigno, Pasquale and Ansari, Jawaher and Caffo, Orazio and Küronya, Zsófia and Vitale, Maria Giuseppa and Bhuva, Dipen and Catalano, Martina and Vau, Nuno and Kopp, Ray Manneh and Buti, Sebastiano and Bamias, Aristotelis and Porta, Camillo and Sunela, Kaisa and Massari, Francesco},
  title = {Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-04043-x}
}
Kostenlos starten →